PDS Biotechnology Co. (NASDAQ:PDSB) to Post Q3 2022 Earnings of ($0.22) Per Share, Oppenheimer Forecasts

PDS Biotechnology Co. (NASDAQ:PDSBGet Rating) – Oppenheimer increased their Q3 2022 earnings estimates for shares of PDS Biotechnology in a note issued to investors on Thursday, May 12th. Oppenheimer analyst L. Gershell now forecasts that the company will earn ($0.22) per share for the quarter, up from their prior forecast of ($0.23). Oppenheimer also issued estimates for PDS Biotechnology’s Q4 2022 earnings at ($0.23) EPS and FY2022 earnings at ($1.03) EPS.

PDS Biotechnology (NASDAQ:PDSBGet Rating) last released its quarterly earnings data on Wednesday, May 11th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.09). During the same period in the prior year, the firm posted ($0.14) EPS.

PDSB has been the subject of several other reports. Noble Financial reiterated a “buy” rating and set a $22.00 price objective on shares of PDS Biotechnology in a research note on Thursday. Zacks Investment Research downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Friday. StockNews.com upgraded shares of PDS Biotechnology to a “sell” rating in a research note on Saturday, April 9th. Finally, Alliance Global Partners decreased their target price on shares of PDS Biotechnology from $18.00 to $16.00 in a research note on Friday. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat, PDS Biotechnology presently has a consensus rating of “Buy” and an average target price of $19.00.

PDSB opened at $4.56 on Monday. PDS Biotechnology has a 52-week low of $3.47 and a 52-week high of $17.85. The company has a 50 day moving average of $5.66 and a two-hundred day moving average of $7.20. The company has a market cap of $129.74 million, a P/E ratio of -5.56 and a beta of 2.34.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its stake in PDS Biotechnology by 7,093.1% during the 4th quarter. Bank of America Corp DE now owns 4,172 shares of the company’s stock valued at $34,000 after acquiring an additional 4,114 shares during the last quarter. UBS Group AG bought a new position in PDS Biotechnology during the 3rd quarter valued at $44,000. Minot Wealth Management LLC bought a new position in PDS Biotechnology during the 1st quarter valued at $62,000. Andesa Financial Management Inc. bought a new position in PDS Biotechnology during the 1st quarter valued at $77,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of PDS Biotechnology during the first quarter worth $89,000. Hedge funds and other institutional investors own 20.94% of the company’s stock.

About PDS Biotechnology (Get Rating)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.

Featured Articles

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.